Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Randomized, Double Blind, Two Arm, Parallel, Placebo-Controlled, Safety and Efficacy Study of Anti-Ageing and Skin Brightening Gel
Authors not listed
NovoBliss Research Pvt Ltd · 2023
Abstract
This is a Randomized, Interventional, Prospective, Double Blind, Two Arm, Comparative, Parallel, Placebo-Controlled, Safety and Efficacy Study of Anti-Ageing and Skin Brightening Gel.
Total of 44 adult female subjects (22 Subjects/Arm) of age 35 - 55 years will be enrolled to get 40 completed subjects (20 Subjects/Arm)
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-06 MST
Cite this
APA
Anonymous. (2023). A Randomized, Double Blind, Two Arm, Parallel, Placebo-Controlled, Safety and Efficacy Study of Anti-Ageing and Skin Brightening Gel. <em>NovoBliss Research Pvt Ltd</em>. https://clinicaltrials.gov/study/NCT06123572
Vancouver
Anonymous. A Randomized, Double Blind, Two Arm, Parallel, Placebo-Controlled, Safety and Efficacy Study of Anti-Ageing and Skin Brightening Gel. NovoBliss Research Pvt Ltd. 2023.
BibTeX
@misc{anon2023ARando,
title = {A Randomized, Double Blind, Two Arm, Parallel, Placebo-Controlled, Safety and Efficacy Study of Anti-Ageing and Skin Brightening Gel},
author = {Anonymous},
journal = {NovoBliss Research Pvt Ltd},
year = {2023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Abinopharm, Inc 2021
Open access · US-GOV
A Multi Center Two Part Study to Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults
Merck Sharp & Dohme LLC 2007
Open access · US-GOV
A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients With Sarcopenia
The University of Hong Kong 2022
Open access · US-GOV
Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With a Novel Treat and Extend Protocol - a Randomized Controlled Prospective Study
Ohr Pharmaceutical Inc. 2016
Open access · US-GOV
OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
University of Aarhus 2021
Open access · US-GOV
Bloodflow Restricted Exercise in Healthy Ageing
Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company 2020
Open access · US-GOV